City File: Zeneca debut
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ZENECA, the drugs and agro-chemicals group that split off from ICI last month, will hit the ground running with its results debut on Thursday. Analysts forecast pre-tax profits in the region of pounds 330m for the half-year, with pharmaceuticals making a healthier showing than the agro-chemicals arm, which has been plagued by a tough market and bad weather.
Pharmaceuticals are expected to contribute nearly 72 per cent of Zeneca's profits for the second quarter, though sales of Tenormin, its ageing heart drug, have slumped 45 per cent a year after expiry of the patent. Sales of Zestril, its other main heart product, and other drugs have gone some way to compensate for the fall, but it has not been enough.
Zeneca's longer-term prospects are for earnings growth of 5 per cent. It is not bad for a struggling sector, but not up with the big boys.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments